Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance

Nilsson, Peter LU ; Hedblad, Bo LU ; Donaldson, Jill and Berglund, Göran LU (2007) In Blood Pressure 16(2). p.95-100
Abstract
Objective. Rosiglitazone (RSG) has been reported to reduce blood pressure (BP) in patients with type-2 diabetes, but similar effects in non-diabetic people with insulin resistance is less clear. Our aim was to test the long-term BP-lowering effects of RSG compared with placebo. Methods. We recruited participants for BP evaluation of RSG treatment from a larger intervention trial. Office BP was recorded in 355 non-diabetic subjects with insulin resistance randomized to receive either RSG or placebo for 52 weeks. Ambulatory BP monitoring (ABPM; Spacelab 90207) was performed in a subgroup of 24 subjects (RSG: n = 11; placebo n = 13). Results. After 1 year, the office BP decreased by -3.1 mmHg systolic (p < 0.05) and -3.8 mmHg diastolic (p... (More)
Objective. Rosiglitazone (RSG) has been reported to reduce blood pressure (BP) in patients with type-2 diabetes, but similar effects in non-diabetic people with insulin resistance is less clear. Our aim was to test the long-term BP-lowering effects of RSG compared with placebo. Methods. We recruited participants for BP evaluation of RSG treatment from a larger intervention trial. Office BP was recorded in 355 non-diabetic subjects with insulin resistance randomized to receive either RSG or placebo for 52 weeks. Ambulatory BP monitoring (ABPM; Spacelab 90207) was performed in a subgroup of 24 subjects (RSG: n = 11; placebo n = 13). Results. After 1 year, the office BP decreased by -3.1 mmHg systolic (p < 0.05) and -3.8 mmHg diastolic (p < 0.001) in the RSG group versus placebo. In patients treated with RSG, at 1 year there was a trend for a reduction from baseline for mean 24-h diastolic BP (DBP), daytime DBP and night-time DBP (- 4.39, -5.26 and -2.93 mmHg, respectively). However, only daytime DBP was significantly lower in the RSG group compared with control (adjusted mean difference: -4.41 mmHg, p=0.007). There was also a non-significant trend for a reduction in mean 24-h systolic BP (SBP), daytime SBP and night-time SBP (-2.70, -2.51 and -3.35 mmHg, respectively). Conclusions. RSG treatment for 1 year was associated with a small but significant decrease in diastolic 24- h ambulatory diastolic BP, and both systolic and diastolic office BPs in non-diabetic people with insulin resistance. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
rosiglitazone, blood pressure, insulin resistance, trial, ambulatory
in
Blood Pressure
volume
16
issue
2
pages
95 - 100
publisher
Taylor & Francis
external identifiers
  • wos:000247933200005
  • scopus:34447323014
  • pmid:17612907
ISSN
0803-7051
DOI
10.1080/08037050701396652
language
English
LU publication?
yes
id
bacea631-b245-4ef4-ae86-ba207c4af64f (old id 645952)
date added to LUP
2016-04-01 12:06:54
date last changed
2022-01-26 22:57:31
@article{bacea631-b245-4ef4-ae86-ba207c4af64f,
  abstract     = {{Objective. Rosiglitazone (RSG) has been reported to reduce blood pressure (BP) in patients with type-2 diabetes, but similar effects in non-diabetic people with insulin resistance is less clear. Our aim was to test the long-term BP-lowering effects of RSG compared with placebo. Methods. We recruited participants for BP evaluation of RSG treatment from a larger intervention trial. Office BP was recorded in 355 non-diabetic subjects with insulin resistance randomized to receive either RSG or placebo for 52 weeks. Ambulatory BP monitoring (ABPM; Spacelab 90207) was performed in a subgroup of 24 subjects (RSG: n = 11; placebo n = 13). Results. After 1 year, the office BP decreased by -3.1 mmHg systolic (p &lt; 0.05) and -3.8 mmHg diastolic (p &lt; 0.001) in the RSG group versus placebo. In patients treated with RSG, at 1 year there was a trend for a reduction from baseline for mean 24-h diastolic BP (DBP), daytime DBP and night-time DBP (- 4.39, -5.26 and -2.93 mmHg, respectively). However, only daytime DBP was significantly lower in the RSG group compared with control (adjusted mean difference: -4.41 mmHg, p=0.007). There was also a non-significant trend for a reduction in mean 24-h systolic BP (SBP), daytime SBP and night-time SBP (-2.70, -2.51 and -3.35 mmHg, respectively). Conclusions. RSG treatment for 1 year was associated with a small but significant decrease in diastolic 24- h ambulatory diastolic BP, and both systolic and diastolic office BPs in non-diabetic people with insulin resistance.}},
  author       = {{Nilsson, Peter and Hedblad, Bo and Donaldson, Jill and Berglund, Göran}},
  issn         = {{0803-7051}},
  keywords     = {{rosiglitazone; blood pressure; insulin resistance; trial; ambulatory}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{95--100}},
  publisher    = {{Taylor & Francis}},
  series       = {{Blood Pressure}},
  title        = {{Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance}},
  url          = {{http://dx.doi.org/10.1080/08037050701396652}},
  doi          = {{10.1080/08037050701396652}},
  volume       = {{16}},
  year         = {{2007}},
}